point of use Latest News

Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers.

IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI.

IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA.

IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing.

Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers.

IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI.

IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA.

IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing.

Personalization of paclitaxel therapy by combination of next generation nanoparticle paclitaxel and point-of-care therapeutic drug monitoring and biomarker testing.

Fera study with Universal Sensors technology shows results in under one hour.